Endo Tries to Upstage Valeant’s Bid for Salix

It’s not over until the fat check arrives. That’s the story of Salix Pharmaceuticals (NASDAQ: SLXP), which last month accepted Valeant Pharmaceuticals’ (NYSE: VRX) $10.1 billion acquisition offer. Valeant thought it had snatched victory from Shire plc (NASDAQ: SHPG) and Endo International plc (NASDAQ: ENDP), which were also readying bids for the troubled Salix. Endo apparently wasn’t daunted, and last week came back with a cash and stock bid of approximately $11.1 billion. Stay tuned.

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *